X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (9) 9
humans (9) 9
male (9) 9
middle aged (9) 9
aged (8) 8
index medicus (8) 8
adult (7) 7
hematology (7) 7
multiple myeloma (7) 7
bortezomib (6) 6
drug therapy (6) 6
life sciences (6) 6
survival (6) 6
dexamethasone (5) 5
stem-cell transplantation (5) 5
abridged index medicus (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cancer (4) 4
chemotherapy (4) 4
dexamethasone - administration & dosage (4) 4
hematology, oncology and palliative medicine (4) 4
therapy (4) 4
[sdv.can]life sciences [q-bio]/cancer (3) 3
disease-free survival (3) 3
hematopoietic stem cell transplantation (3) 3
kaplan-meier estimate (3) 3
melphalan (3) 3
multiple myeloma - drug therapy (3) 3
multiple myeloma - therapy (3) 3
oncology (3) 3
plus dexamethasone (3) 3
prednisone (3) 3
stem cell transplantation (3) 3
[ sdv.can ] life sciences [q-bio]/cancer (2) 2
[ sdv.imm ] life sciences [q-bio]/immunology (2) 2
[sdv.mhep.hem]life sciences [q-bio]/human health and pathology/hematology (2) 2
amyloidosis - drug therapy (2) 2
amyloidosis - mortality (2) 2
antineoplastic agents (2) 2
autografts (2) 2
blood (2) 2
carfilzomib (2) 2
comparative analysis (2) 2
daratumumab (2) 2
dosage and administration (2) 2
drug therapy, combination (2) 2
france (2) 2
high-dose chemotherapy (2) 2
human health and pathology (2) 2
immunology (2) 2
lenalidomide (2) 2
low-dose dexamethasone (2) 2
medicine, general & internal (2) 2
melphalan - administration & dosage (2) 2
multicenter (2) 2
multiple myeloma - complications (2) 2
multiple myeloma - mortality (2) 2
multiple-myeloma (2) 2
open-label (2) 2
patients (2) 2
peripheral neuropathy (2) 2
primary systemic amyloidosis (2) 2
randomized-trial (2) 2
recurrence (2) 2
stem cells (2) 2
thalidomide (2) 2
thalidomide - administration & dosage (2) 2
thalidomide - adverse effects (2) 2
thalidomide - analogs & derivatives (2) 2
thalidomide - therapeutic use (2) 2
transplantation (2) 2
[sdv.imm]life sciences [q-bio]/immunology (1) 1
administration, oral (1) 1
adolescent (1) 1
aged, 80 and over (1) 1
agents (1) 1
amyloidosis (1) 1
amyloidosis - therapy (1) 1
anti-inflammatory agents - administration & dosage (1) 1
anti-inflammatory agents - adverse effects (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
association (1) 1
bone diseases - etiology (1) 1
bone marrow (1) 1
bone neoplasms - drug therapy (1) 1
bone neoplasms - mortality (1) 1
boronic acids - administration & dosage (1) 1
bortezomib - administration & dosage (1) 1
brain natriuretic peptide (1) 1
canada (1) 1
cancer research (1) 1
cardiac troponins (1) 1
care and treatment (1) 1
child (1) 1
child, preschool (1) 1
children (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1782 - 1791
Journal Article
Blood, ISSN 0006-4971, 11/2017, Volume 130, Issue 22, pp. 2401 - 2409
Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring... 
INTERGROUPE FRANCOPHONE | IMPACT | CARFILZOMIB | RESPONSE CRITERIA | T(11/14)(Q13,Q32) | CHRONIC LYMPHOCYTIC-LEUKEMIA | DARATUMUMAB MONOTHERAPY | OPEN-LABEL | BORTEZOMIB | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Life Sciences | Cancer
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2006, Volume 108, Issue 10, pp. 3289 - 3294
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2007, Volume 357, Issue 11, pp. 1083 - 1093
Journal Article
Blood, ISSN 0006-4971, 2015, Volume 126, Issue 23, pp. 4245 - 4245
Background. Bortezomib-melphalan-prednisone (VMP) and melphalan-prednisone-Thalidomide (MPT) are the 2 standards of care upfront in Multiple Myeloma (MM)... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 978 - 978
Abstract Multiple myeloma (MM) is often revealed by acute kidney injury (AKI) usually related to MCN. Recovery of renal function is a key prognostic factor.... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 4637 - 4637
Abstract Introduction Renal impairment occurs in 20-30% of newly diagnosed multiple myeloma patients, requiring dialysis for up to 10% of patients.Recent... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 488 - 488
Abstract Background: Venetoclax (VEN) is a potent, selective, orally available small-molecule BCL-2 inhibitor that induces cell death in multiple myeloma (MM)... 
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 10/2019, Volume 19, Issue 10, pp. e245 - e246
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2/2013, Volume 71, Issue 2, pp. 399 - 404
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 1151 - 1151
Abstract Introduction: Daratumumab is a human monoclonal antibody targeting CD38 that demonstrated superior efficacy in combination with lenalidomide and... 
Journal Article